October 4, 2021 09:50 AM EDTUpdated October 8, 12:53 AM

Thermo Fisher expands into Switzerland as part of CSL collaboration

Josh Sullivan

Just days after Thermo Fisher Scientific prepped to expand a St. Louis plant, the company announced it’s taking over a new, 1.5 million-square-foot site in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Thermo Fisher expands into Switzerland as part of CSL collaboration

Josh Sullivan

Sign up to read this article for free.

FDA declines to approve Ultragenyx's Sanfilippo gene therapy, citing manufacturing issues

AstraZeneca posts a pivotal trial win for blood pressure pill behind $1.3B deal

Takeda’s first-in-class narcolepsy drug succeeds in two registrational studies

Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays

FDA's Makary calls for tying fast-review vouchers to lower US prices, without specifics

Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash

Ther­mo Fish­er ex­pands in­to Switzer­land as part of CSL col­lab­o­ra­tion

Josh Sullivan

Sign up to read this article for free.

more like this

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Take­da’s first-in-class nar­colep­sy drug suc­ceeds in two reg­is­tra­tional stud­ies

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

FDA's Makary calls for ty­ing fast-re­view vouch­ers to low­er US prices, with­out specifics

Karyopharm cuts 20% of staff as it looks at 's­trate­gic al­ter­na­tives' or rais­ing cash

Thermo Fisher expands into Switzerland as part of CSL collaboration

FDA declines to approve Ultragenyx's Sanfilippo gene therapy, citing manufacturing issues

AstraZeneca posts a pivotal trial win for blood pressure pill behind $1.3B deal

Takeda’s first-in-class narcolepsy drug succeeds in two registrational studies

Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays

FDA's Makary calls for tying fast-review vouchers to lower US prices, without specifics

Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash